164 related articles for article (PubMed ID: 8355145)
21. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins.
Sharma US; Balasubramanian SV; Straubinger RM
J Pharm Sci; 1995 Oct; 84(10):1223-30. PubMed ID: 8801338
[TBL] [Abstract][Full Text] [Related]
22. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system.
Higashi T; Hirayama F; Misumi S; Arima H; Uekama K
Biomaterials; 2008 Oct; 29(28):3866-71. PubMed ID: 18620750
[TBL] [Abstract][Full Text] [Related]
23. Differential effects of modified beta-cyclodextrins on pharmacological activity and bioavailability of 4-biphenylacetic acid in rats after oral administration.
Puglisi G; Ventura CA; Spadaro A; Campana G; Spampinato S
J Pharm Pharmacol; 1995 Feb; 47(2):120-3. PubMed ID: 7602465
[TBL] [Abstract][Full Text] [Related]
24. Enhanced nasal delivery of luteinizing hormone releasing hormone agonist buserelin by oleic acid solubilized and stabilized in hydroxypropyl-beta-cyclodextrin.
Abe K; Irie T; Uekama K
Chem Pharm Bull (Tokyo); 1995 Dec; 43(12):2232-7. PubMed ID: 8582025
[TBL] [Abstract][Full Text] [Related]
25. Improvement of Pharmaceutical Properties of Zerumbone, a Multifunctional Compound, Using Cyclodextrin Derivatives.
Hassan MM; Mohammed AFA; Elamin KM; Devkota HP; Ohno Y; Motoyama K; Higashi T; Imai T
Chem Pharm Bull (Tokyo); 2020; 68(11):1117-1120. PubMed ID: 33132380
[TBL] [Abstract][Full Text] [Related]
26. Utility of 2-hydroxypropyl-beta-cyclodextrin in an intramuscular injectable preparation of nimodipine.
Yoshida A; Yamamoto M; Itoh T; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1990 Jan; 38(1):176-9. PubMed ID: 2337940
[TBL] [Abstract][Full Text] [Related]
27. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats.
Arima H; Yunomae K; Miyake K; Irie T; Hirayama F; Uekama K
J Pharm Sci; 2001 Jun; 90(6):690-701. PubMed ID: 11357172
[TBL] [Abstract][Full Text] [Related]
28. [Improvement of stability and bioavailability of 1-hexylcarbamoyl-5-fluorouracil (HCFU) by O-carboxymethyl-O-ethyl-beta- cyclodextrin].
Horiuchi Y; Hirayama F; Uekama K
Yakugaku Zasshi; 1991 Oct; 111(10):592-9. PubMed ID: 1812279
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of the antiinflammatory effect of ethyl 4-biphenylyl acetate in ointment by beta-cyclodextrin derivatives: increased absorption and localized activation of the prodrug in rats.
Arima H; Adachi H; Irie T; Uekama K; Pitha J
Pharm Res; 1990 Nov; 7(11):1152-6. PubMed ID: 2293214
[TBL] [Abstract][Full Text] [Related]
30. Design and evaluation of folate-appended α-, β-, and γ-cyclodextrins having a caproic acid as a tumor selective antitumor drug carrier in vitro and in vivo.
Okamatsu A; Motoyama K; Onodera R; Higashi T; Koshigoe T; Shimada Y; Hattori K; Takeuchi T; Arima H
Biomacromolecules; 2013 Dec; 14(12):4420-8. PubMed ID: 24175976
[TBL] [Abstract][Full Text] [Related]
31. Polypseudorotaxane formation of randomly-pegylated insulin with cyclodextrins: slow release and resistance to enzymatic degradation.
Higashi T; Hirayama F; Misumi S; Motoyama K; Arima H; Uekama K
Chem Pharm Bull (Tokyo); 2009 May; 57(5):541-4. PubMed ID: 19420793
[TBL] [Abstract][Full Text] [Related]
32. Sustained release of flufenamic acid from a drug-triacetyl-beta-cyclodextrin complex.
Nakanishi K; Masukawa T; Nadai T; Yoshii K; Okada S; Miyajima K
Biol Pharm Bull; 1997 Jan; 20(1):66-70. PubMed ID: 9013809
[TBL] [Abstract][Full Text] [Related]
33. Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by beta-cyclodextrin derivatives in hydrophilic ointment.
Arima H; Miyaji T; Irie T; Hirayama F; Uekama K
Chem Pharm Bull (Tokyo); 1996 Mar; 44(3):582-6. PubMed ID: 8882455
[TBL] [Abstract][Full Text] [Related]
34. Sustained release of buserelin acetate, a luteinizing hormone-releasing hormone agonist, from an injectable oily preparation utilizing ethylated beta-cyclodextrin.
Uekama K; Arima H; Irie T; Matsubara K; Kuriki T
J Pharm Pharmacol; 1989 Dec; 41(12):874-6. PubMed ID: 2576455
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in cyclodextrin delivery techniques.
Arima H; Hayashi Y; Higashi T; Motoyama K
Expert Opin Drug Deliv; 2015; 12(9):1425-41. PubMed ID: 26098975
[TBL] [Abstract][Full Text] [Related]
36. In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcelluloses in dogs.
Wang Z; Hirayama F; Uekama K
J Pharm Pharmacol; 1994 Jun; 46(6):505-7. PubMed ID: 7932048
[TBL] [Abstract][Full Text] [Related]
37. Improvement of some physicochemical properties of arundic acid, (R)-(-)-2-propyloctanonic acid, by complexation with hydrophilic cyclodextrins.
Miyamoto Y; Nakahara M; Motoyama K; Ishiguro T; Oda Y; Yamanoi T; Okamoto I; Yagi A; Nishimura H; Hirayama F; Uekama K; Arima H
Int J Pharm; 2011 Jul; 413(1-2):63-72. PubMed ID: 21540089
[TBL] [Abstract][Full Text] [Related]
38. Study of the interaction of clobazam with cyclodextrins in solution and in the solid state.
Nakai Y; el-Said Aboutaleb A; Yamamoto K; Saleh SI; Ahmed MO
Chem Pharm Bull (Tokyo); 1990 Mar; 38(3):728-32. PubMed ID: 2347015
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies.
Nagase Y; Arima H; Wada K; Sugawara T; Satoh H; Hirayama F; Uekama K
J Pharm Sci; 2003 Dec; 92(12):2466-74. PubMed ID: 14603492
[TBL] [Abstract][Full Text] [Related]
40. Potential use of polypseudorotaxanes of pegylated polyamidoamine dendrimer with cyclodextrins as novel sustained release systems for DNA.
Motoyama K; Hayashida K; Arima H
Chem Pharm Bull (Tokyo); 2011; 59(4):476-9. PubMed ID: 21467677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
